Hong Kong stock market anomaly | CStone Pharmaceuticals-B (09606.HK) rises more than 5% after completing the administration of the first patient in the global Phase III clinical trial of B7-H3 ADC developed in collaboration with BioNTech.
According to the Wisdom Financial APP, Ying En Biology-B (09606.HK) has risen by more than 5%, as of the time of publication, it has increased by 3.14% to 222.6 Hong Kong dollars, with a trading volume of 152 million Hong Kong dollars.
Latest
